Anh Tu Thai

Anh Tu Thai

Auto-generated profile, based on publicly available information

Anh Tu Thai

Department of Pathology, Oncology Hospital, Ho Chi Minh City, Vietnam

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2026 in Histopathology
Verified
Journal Article
Open access
CDCorrado D'ARrigo
Corrado D'ARrigo
STSitki Tuzlali
Sitki Tuzlali
RBRomualdo Barroso-Sousa
Romualdo Barroso-Sousa
NSNagi S El Saghir
Nagi S El Saghir
RDRebecca Dent
Rebecca Dent
LPLazar Popović
Lazar Popović
Aim: To understand whether the worldwide implementation of PD‐L1 testing in triple‐negative breast cancer (TNBC) can be achieved in routine clinical practice. Methods and results: The multicentre retrospective observational VANESSA study consecutively and uniformly enrolled patients treated with systemic therapy for early or metastatic (e/m)TNBC diagnosed between 2014 and 2017. PD‐L1 status was retrospectively assessed locally and centrally using the VENTANA PD‐L1 (SP142) Assay (PD‐L1 expression on tumour‐infiltrating immune cells covering ≥1% of the tumour area). The primary objective was to determine the prevalence of PD‐L1 positivity assessed locally on primary and/or metastatic tumour tissue. Concordance between local and central testing was a secondary endpoint. PD‐L1‐positive prevalence was 38% in eTNBC (728/1902) and 20% in mTNBC (30/152) and was higher in submitted tissue size >5 versus <5 mm diameter (eTNBC: 43% versus 16%; mTNBC: 24% versus 13%). Among 1967 samples tested both centrally and locally, concordance was 75% (Cohen's κ coefficient 0.52, 95% CI 0.48–0.55) and was similar regardless of cohort (eTNBC versus mTNBC), sample collection method (biopsy versus resection) or sample origin (primary versus metastatic). PD‐L1‐positive prevalence was higher by central versus local assessment (eTNBC: 55% versus 39%; mTNBC: 26% versus 20%). Conclusion: In this real‐world study, PD‐L1‐positive prevalence was lower than in prospective trials assessing PD‐L1 status centrally, lower in mTNBC than eTNBC, lower in smaller than larger tissue samples and lower by local than central assessment. These findings underline the importance of central PD‐L1 testing on sufficiently large samples to ensure optimal selection for therapies targeting PD‐(L)1 in mTNBC.

15 March 2025 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
QPQuoc Thang Pham
Quoc Thang Pham
QPQuoc Thang Pham
Quoc Thang Pham
MNMinh Nguyen
Minh Nguyen
HNHoa Nhat Ngo
Hoa Nhat Ngo
TLThao Thi Thu Luu
Thao Thi Thu Luu
DNDat Quoc Ngo
Dat Quoc Ngo
Background: The RET gene point mutation is the main molecular alteration involved in medullary thyroid carcinoma (MTC) tumorigenesis. Previous studies in Vietnam mainly consisted of case reports, with limited data on larger sample sizes. In this study, we investigated RET gene mutations in exons 10, 11, and 16 and analyzed clinicopathological features of a series of Vietnamese MTC patients. Methods: We collected 33 tissue samples from patients with MTC and analyzed RET mutations using the Sanger sequencing method. The relationship between hotspot RET mutations (exons 10, 11, 16) and clinicopathological features were investigated. Results: Among the 33 analyzed cases, 17 tumors (52%) harbored RET mutations in exon 10, 11, or 16. A total of 10 distinct genetic alterations were identified, including eight missense mutations and two short indels. Of these, seven were classified as pathogenic mutations based on previous publications, with p.M918T being the most frequent (4 cases), followed by p.C634R (3 cases) and p.C618R (3 cases). Mutations were significantly associated with specific histological patterns, such as the nested/insular pattern (p=.026), giant cells (p=.007), nuclear pleomorphism (p=.018), stippled chromatin (p=.044), and amyloid deposits (p=.024). No mutations were found in germline analyses, suggesting these were somatic alterations. Conclusions: Our results provided the first comprehensive analysis of RET mutations in Vietnamese MTC patients. The most frequent mutation was p.M918T, followed by p.C634R and p.C618R. Mutations in these three exons were linked to specific histopathological features. Information on mutational profiles of patients with MTC will further aid in the development of targeted therapeutics to ensure effective disease management.

15 July 2026 in Diagnostic Pathology
Verified
Journal Article
Open access
GTGiang Huong Tran
Giang Huong Tran
DTDuyen Hoang-My Truong
Duyen Hoang-My Truong
LNLam Ngoc Nguyen
Lam Ngoc Nguyen
TTTu Anh Thai
Tu Anh Thai
KLKhoa Anh Luong
Khoa Anh Luong
Background: PRAME immunohistochemistry is a useful adjunct in distinguishing melanoma from benign melanocytic lesions, but its clinicopathologic associations remain incompletely understood, particularly in underrepresented populations. Methods: This retrospective study included 90 primary melanomas and 90 melanocytic nevi from a Vietnamese cohort. PRAME expression (clone EPR20330) was assessed using a semi-quantitative scoring system: 0 (0%), 1+ (1–25%), 2+ (26–50%), 3+ (51–75%), and 4+ (> 75% of tumor cells with nuclear positivity), with 4 + defined as high expression. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, and associations with clinicopathologic variables were analyzed using logistic regression. Results: The mean age of melanoma patients was 56.4 ± 15.9 years, with a median tumor size of 30 mm. Nodular melanoma was the most common subtype (60%), and mucosal melanoma accounted for 15.6%. Adverse features were common, including Breslow thickness > 1 mm (87.8%), mitotic rate > 1/mm² (85.6%), and ulceration (36%). High PRAME expression was observed in 73.3% of melanomas, whereas 97.8% of nevi were negative and none showed PRAME ≥ 2+. PRAME demonstrated excellent diagnostic performance (AUC 0.936), with sensitivity, specificity, and accuracy of 87.8%, 97.8%, and 92.8% at a cutoff of ≥ 1+. Tumor size > 12 mm was independently associated with high PRAME expression in the overall cohort but not in cutaneous melanoma. No statistically significant associations were observed between PRAME expression and tumor stage in cutaneous melanoma. Conclusions: In this predominantly advanced-stage Vietnamese cohort, PRAME immunohistochemistry showed high sensitivity and specificity in distinguishing melanoma from nevi; its performance in early or thin melanomas and its broader clinicopathologic significance remain to be clarified in future studies.